Evotec SE has signed a landmark agreement with Sandoz, involving the sale of its Just – Evotec Biologics site for approximately US$ 350 million, plus additional fees, marking a strategic shift towards an asset-light business model.

Information on the Target

Evotec SE, a life science company headquartered in Hamburg, Germany, is at the forefront of drug discovery and development. The company has established itself as a leader in biologics manufacturing, particularly through its Just – Evotec Biologics subsidiary, which was the subject of a recent transaction with Sandoz AG. This acquisition allows Sandoz to expand their capabilities in producing biologics while benefiting from Evotec's advanced continuous manufacturing technology.

As part of the agreement, Sandoz will acquire Evotec’s Just – Evotec Biologics manufacturing site in Toulouse. This acquisition includes not just the physical asset but also an indefinite license to use Evotec’s proprietary continuous manufacturing platform, which enhances efficiency and reduces costs in biologics production.

Industry Overview in Germany

The German biopharmaceutical industry is a key pillar of the global life sciences sector, characterized by innovation and strong research capabilities. Home to many of the world’s leading pharmaceutical companies, Germany inv